Research and development of products in the segment of living poultry vaccines (Q2727901)
Jump to navigation
Jump to search
Project Q2727901 in Croatia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Research and development of products in the segment of living poultry vaccines |
Project Q2727901 in Croatia |
Statements
11,658,803.09 Croatian kuna
0 references
28,223,776.27 Croatian kuna
0 references
85.0 percent
0 references
19 April 2018
0 references
12 June 2021
0 references
Genera dioničko društvo za razvoj i proizvodnju farmaceutskih proizvoda
0 references
45°47'48.26"N, 15°46'34.64"E
0 references
10431
0 references
Svrha projekta je podići globalnu konkurentnost Genera d.d. razvojem i plasmanom inovativnog veterinarsko-medicinskog proizvoda - novog programa živih (atenuiranih) liofiliziranih cjepiva od četiri cjepna soja, za kombiniranu primjenu i sinergistički efekt prlikom tretiranja infektivnog bronhitisa i zarazne bolesti burze u peradi, kao i jačanjem istraživačko-razvojnih kapaciteta tvrtke. (Croatian)
0 references
The project aims to strengthen the global competitiveness of Genera d.d. through the development and placement of innovative veterinary medicinal products — new alive (attenuated) lyophilised vaccines of four vaccine vaccinated strains, for the combined use and synergistic effect of infective bronchitis and contagious animal exchange diseases, as well as by strengthening the company’s research and development research and development capacity. (English)
3 June 2021
0 references
Svrha projekta je podići globalnu konkurentnost Genera d.d. razvojem i plasmanom inovativnog veterinarsko-medicinskog proizvoda — novog programa živih (atenuiranih) liofiliziranih cjepiva od četiri cjepna soja, za kombiniranu primjenu i sinergistički efekt prlikom tretiranja infektivnog bronhitisa i zarazne bolesti Burze u Peradi, kao i jačanjem istraživačko-razvojnih kapaciteta tvrtke. (French)
26 November 2021
0 references
Ziel des Projekts ist es, die globale Wettbewerbsfähigkeit von Genera d.d. durch die Entwicklung und Vermarktung eines innovativen Tierarzneimittels – ein neues Programm lebender (attenuierter) lyophilisierter Impfstoffe von vier Impfstoffstämmen – für die kombinierte Anwendung und synergistische Wirkung der Behandlung infektiöser Bronchitis und Infektionskrankheiten des Geflügelbestands sowie die Stärkung der Forschungs- und Entwicklungskapazitäten des Unternehmens zu erhöhen. (German)
29 November 2021
0 references
Identifiers
KK.01.2.1.01.0092
0 references